- Immunocore reports first quarter financial results and provides a business update
- EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
- Immunocore announces upcoming presentation and posters at ASCO 2024
- Immunocore to present at upcoming investor conferences
- Immunocore presented two posters at CROI 2024
- Immunocore to present at upcoming investor conferences
- Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
- Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
- Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
- Immunocore Prices Upsized Convertible Senior Notes Offering
More ▼
Key statistics
On Tuesday, Immunocore Holdings PLC (6YG:DEU) closed at 56.50, -20.42% below its 52-week high of 71.00, set on Feb 01, 2024.
52-week range
Open | 56.50 |
---|---|
High | 57.50 |
Low | 56.00 |
Bid | 56.50 |
Offer | 57.00 |
Previous close | 57.50 |
Average volume | 29.20 |
---|---|
Shares outstanding | 49.98m |
Free float | 44.13m |
P/E (TTM) | -- |
Market cap | 3.05bn USD |
EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of May 07 2024.
More ▼